Idioma:

Idarucizumab for Dabigatran Reversal — Full Cohort Analysis

Pollack, Charles V ; Reilly, Paul A ; van Ryn, Joanne ; Eikelboom, John W ; Glund, Stephan ; Bernstein, Richard A ; Dubiel, Robert ; Huisman, Menno V ; Hylek, Elaine M ; Kam, Chak-Wah ; Kamphuisen, Pieter W ; Kreuzer, Jörg ; Levy, Jerrold H ; Royle, Gordon ; Sellke, Frank W ; Stangier, Joachim ; Steiner, Thorsten ; Verhamme, Peter ; Wang, Bushi ; Young, Laura ; Weitz, Jeffrey I

The New England journal of medicine, 2017-08, Vol.377 (5), p.431-441 [Periódico revisado por pares]

United States: Massachusetts Medical Society

Texto completo disponível

Citações Citado por

Enviar para

Título:
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis
Autor: Pollack, Charles V ; Reilly, Paul A ; van Ryn, Joanne ; Eikelboom, John W ; Glund, Stephan ; Bernstein, Richard A ; Dubiel, Robert ; Huisman, Menno V ; Hylek, Elaine M ; Kam, Chak-Wah ; Kamphuisen, Pieter W ; Kreuzer, Jörg ; Levy, Jerrold H ; Royle, Gordon ; Sellke, Frank W ; Stangier, Joachim ; Steiner, Thorsten ; Verhamme, Peter ; Wang, Bushi ; Young, Laura ; Weitz, Jeffrey I
Assuntos: Adult ; Aged ; Aged, 80 and over ; Antibodies - blood ; Antibodies, Monoclonal, Humanized - adverse effects ; Antibodies, Monoclonal, Humanized - immunology ; Antibodies, Monoclonal, Humanized - therapeutic use ; Anticoagulants ; Anticoagulants - adverse effects ; Bleeding ; Blood Coagulation - drug effects ; Clotting ; Cohort analysis ; Dabigatran - adverse effects ; Dabigatran - antagonists & inhibitors ; Dabigatran - blood ; Drug dosages ; Drug Hypersensitivity ; Drug therapy ; Female ; Hemorrhage ; Hemorrhage - chemically induced ; Hemorrhage - drug therapy ; Hemostasis ; Humans ; Infusions, Intravenous ; Intravenous administration ; Male ; Middle Aged ; Monoclonal antibodies ; Mortality ; Patients ; Preventive medicine ; Prospective Studies ; Surgery ; Thrombin ; Thrombin Time ; Thrombosis ; Thrombosis - chemically induced ; Time Factors
É parte de: The New England journal of medicine, 2017-08, Vol.377 (5), p.431-441
Descrição: Idarucizumab was 100% effective in reversing the anticoagulant effect of dabigatran among 300 patients with uncontrolled bleeding (median time to bleeding cessation, 2.5 hours) and among 200 patients who required an urgent procedure (median time to procedure initiation, 1.6 hours).
Editor: United States: Massachusetts Medical Society
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Idarucizumab for Dabigatran Reversal — Full Cohort Analysis

United States: Massachusetts Medical Society

Buscando em bases de dados remotas. Favor aguardar.